Publications by authors named "A Cubas"
Regulatory T cells (Tregs) are promising cellular therapies to induce immune tolerance in organ transplantation and autoimmune disease. The success of chimeric antigen receptor (CAR) T cell therapy for cancer has sparked interest in using CARs to generate antigen-specific Tregs. Here, we compared CAR with endogenous T cell receptor (TCR)/CD28 activation in human Tregs.
View Article and Find Full Text PDFMost children with medulloblastoma (MB) achieve remission, but some face very aggressive metastatic tumors. Their dismal outcome highlights the critical need to advance therapeutic approaches that benefit such high-risk patients. Minnelide, a clinically relevant analog of the natural product triptolide, has oncostatic activity in both preclinical and early clinical settings.
View Article and Find Full Text PDFArticle Synopsis
- PDAC is the most common and lethal pancreatic cancer, marked by high levels of HSP70, which relates to poor patient outcomes and aggressive tumor behavior.
- HSP70's overexpression in PDAC disrupts mitochondrial function and promotes cancer cell survival, while its inhibition leads to mitochondrial dysfunction and programmed cell death.
- Targeting HSP70, especially in combination with autophagy inhibitors like hydroxychloroquine, could be a promising strategy for treating HSP70-driven PDAC.
Unlabelled: Chronic lymphocytic leukemia (CLL) cell survival and growth is fueled by the induction of B-cell receptor (BCR) signaling within the tumor microenvironment (TME) driving activation of NFκB signaling and the unfolded protein response (UPR). Malignant cells have higher basal levels of UPR posing a unique therapeutic window to combat CLL cell growth using pharmacologic agents that induce accumulation of misfolded proteins. Frontline CLL therapeutics that directly target BCR signaling such as Bruton tyrosine kinase (BTK) inhibitors (e.
View Article and Find Full Text PDFArticle Synopsis
- - The study explores the use of chimeric antigen receptor (CAR) Tregs as a potential therapy for immune tolerance in organ transplantation and autoimmune diseases, comparing them to traditional TCR/CD28 activated Tregs.
- - CAR Tregs demonstrated higher cytotoxicity and less suppression of antigen-presenting cells and effector T cells, along with significant activation of gene programs associated with effector cells.
- - The research suggests that by modifying the affinity of CAR antigens, it is possible to influence the inflammatory response and gene expression of CAR Tregs, indicating the potential for tailored CAR designs to improve their therapeutic effect.